Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mrsic, M.
Right arrow Articles by Gosev, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mrsic, M.
Right arrow Articles by Gosev, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:S95-S96, 2001
© 2001 European Society for Medical Oncology

Symposium Article

Trastuzumab in the treatment of advanced breast cancer: Single-center experience

M. Mrsic1, M. Grgic1, Z. Budisic1, P. Podolski1, V. Bogdanic1, B. Labar1, J. Jakic-Razumovic1, N. Restek-Samarzija2 and M. Gosev1,2

1 University Hospital Center Zagreb Zagreb, Croatia
2 F. Hoffmann-La Roche Ltd, Representation Office Zagreb, Croatia

Correspondence to: M. Mrsic, MD University Hospital Center Zagreb Kispatic str 12 10 000 Zagreb Croatia E-mail: mirando.mrsic{at}inet.hr

A significant number of women with advanced breast cancer fail to respond to standard-dose chemotherapy. From the beginning of 1999, 17 women with HER2 positive advanced breast cancer received Herceptin-> as monotherapy or in combination with paclitaxel or other non-anthracyclines. Eight (47%) women previously received high-dose chemotherapy followed by haematopoiesis stem cell rescue. Three women received Herceptin-> alone, eleven Herceptin-> plus paclitaxel and three Herceptin-> and some of the other non-anthracyclines (CCNU, cisplatin and gemcitabine). In the group of patients who received Herceptin-> monotherapy, one has partial response (PR), one stable disease (SD) and in the third patient the disease progressed. Out of three patients who received Herceptin-> in combination with other non-anthracyclines, two have SD and one progressed. In the group of 11 women who received Herceptin-> + Taxol->, 7 (64%) patients achieved PR, 2 (18%) SD, and 2 (18%) had disease progression. Grade 3–4 neutropenia has been observed in four (23%) women. Febrile neutropenia was observed in two cases and resolved completely when antibiotics were introduced. Other grade 3 toxicity that has been noted is peripheral neuropathy in three (18%) patients, diarrhoea in four (23%) and onycholysis in one (6%). Serial heart ultrasound showed no significant decline in left ventricular ejection fraction. According to our preliminary experience, Herceptin-> therapy showed promising results in women with metastatic breast cancer.

anti-HER2 monoclonal antibody, HER2


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 GutHome page
J K Ramage, A H G Davies, J Ardill, N Bax, M Caplin, A Grossman, R Hawkins, A M McNicol, N Reed, R Sutton, et al.
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours
Gut, June 1, 2005; 54(suppl_4): iv1 - iv16.
[Full Text] [PDF]

Home page
 Ann OncolHome page
M. Piccart, L. M. Parker, and K. I. Pritchard
Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer
Ann. Onc., July 1, 2003; 14(7): 1017 - 1025.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.